Clinical Trial Update: A Study of HMBD-002, a Monoclonal Antibody Targeting VISTA, as Monotherapy and Combined With Pembrolizumab, in Patients With Advanced Solid Tumors [Phase 1]

View source ↗

Summary

This is a completed Phase 1 trial of HMBD-002, a VISTA-targeting monoclonal antibody, as monotherapy and with pembrolizumab in patients with advanced solid tumo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• HMBD-002 (HMBD-002)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Hummingbird Bioscience | Conditions: Cancer, Tumor, Solid | Phase 1 | Status: COMPLETED